Italia markets open in 6 hours 11 minutes

Arbutus Biopharma Corporation (0SGC.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,9015-0,5005 (-20,84%)
Alla chiusura: 06:45PM BST
Schermo intero
Chiusura precedente2,4020
Aperto1,9150
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,9015 - 1,9150
Intervallo di 52 settimane1,9015 - 1,9150
Volume1.140
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)2,23
Rapporto PE (ttm)N/D
EPS (ttm)-0,7050
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference

    WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET. Presenters: William Collier, President & Chief Executive O

  • GlobeNewswire

    Arbutus to Participate in September Investor Conferences

    WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022) Company Presentation: Tuesday, September 13t

  • GlobeNewswire

    Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

    WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,427,823, which provides composition of matter patent protection for Arbutus’ AB-729 RNAi therapeutic product. The patent is expected to provide Arbu